Cargando…
Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma
BACKGROUND: Current standard of treatment for newly diagnosed patients with glioblastoma (GBM) is surgical resection with adjuvant normofractionated radiotherapy (NFRT) combined with temozolomide (TMZ) chemotherapy. Hyperfractionated accelerated radiotherapy (HFRT) which was known as an option from...
Autores principales: | Lewitzki, Victor, Klement, Rainer J., Kosmala, Rebekka, Lisowski, Dominik, Flentje, Michael, Polat, Bülent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909505/ https://www.ncbi.nlm.nih.gov/pubmed/31831026 http://dx.doi.org/10.1186/s13014-019-1427-5 |
Ejemplares similares
-
Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis
por: Klement, Rainer J., et al.
Publicado: (2021) -
Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016) -
Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma
por: Polat, Bülent, et al.
Publicado: (2022) -
Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation
por: Niewald, Marcus, et al.
Publicado: (2011) -
Radiochemotherapy
Publicado: (1998)